Whereas serum NfL may have utility as a molecular marker for neurodegeneration of the brain and spinal cord for patients with Alzheimer's disease, traumatic brain injury, multiple sclerosis, and Parkinson's disease,13,27–30 its clinical utility in glaucoma, and ocular disease more broadly, may be limited. This evidence concerns the gene NEFL and early-onset autosomal dominant Alzheimer disease.